Anglo-Swedish drugmaker AstraZeneca said a study of its monoclonal antibody treatment, AZD7442, did not meet the main goal of preventing symptomatic COVID-19 in people recently exposed to the novel coronavirus.
Anglo-Swedish drugmaker AstraZeneca said on Tuesday a study of its monoclonal antibody treatment, AZD7442, did not meet the main goal of preventing
AstraZenecasaid on Tuesday a study of its monoclonal antibody treatment, AZD7442, did not meet the main goal of preventing symptomatic COVID-19 in people recently exposed to the novel coronavirus.The company said the participants in the trial were unvaccinated adults older than 18 years with confirmed exposure to a person with the coronavirus within the past eight days.
AZD7442 reduced the risk of developing symptomatic COVID-19 by 33% compared to a placebo, which was not statistically significant, the company reported.“While this trial did not meet the primary endpoint against symptomatic illness, we are encouraged by the protection seen in the PCR negative participants following treatment with AZD7442,” Mene Pangalos,
AstraZenecaexecutive vice president, said in a statement.AstraZenecais also studying the treatment in a pre-exposed patients trial and for preventing more severe disease.The monoclonal antibody therapy belongs to a class of drugs which mimic natural antibodies the body produces to fight off the infection. headtopics.com
Rivals Regeneron Pharmaceuticals Inc and Eli Lilly & Co have both developed monoclonal antibody therapies which have been authorized for use in the United States to treat patients infected with the virus.. The European Medicines Agency (EMA) has approved Regeneron’s therapy and is reviewing similar drugs from Eli Lilly, Celltrion and one developed by GlaxoSmithKline and Vir Biotechnology Inc.
AstraZenecain October enlisted Swiss contract manufacturer Lonza to produce the antibody drug in Portsmouth, New Hampshire, starting in the first half of 2021.AZD7442 is being developed with support from the U.S. government.AstraZenecain March announced a deal with the U.S. government to supply up to half a million doses of AZD7442. The company said on Tuesday it is now in talks with the U.S. government regarding next steps on the deal.Read more: Interaksyon »
Metro.Style: Every Woman’s Guide to a Well-Styled Life
Your ultimate source for the best curated content on fashion, beauty, and lifestyle brought to you by the Metro Superbrand
Digos City reverts to GCQ until June 27 as COVID-19 cases soarDigos City in Davao del Sur will be again placed under a stricter quarantine classification due to the 'exponential' rise of COVID-19 cases in the area.
How satellites help fight COVID-19 in PHOr is this a human monitoring same as with china human monitoring... Whatever happened to privacy... I still want my privacy!
Population protection vs COVID-19 achieved by December, Palace assures😂😂😂😂
New Covid-19 cases continue to top 6,000 a dayEVEN with 10 laboratories failing to report their testing output two days earlier, new coronavirus infections still exceeded 6,000 in a day for the...
TIMELINE: COVID-19 vaccine deliveries and rollout in the PhilippinesOnly 1.7% of 108 million Filipinos have fully completed their doses, three months after the government started the simultaneous vaccine drive in the country.
How did Wil Dasovich's mom survive COVID-19?Charry Lising-Dasovich was among the thousands who contracted the dreaded virus during the COVID-19 surge in April 2021.